Perrigo downgraded to Hold from Buy at Argus Argus analyst Jacob Kilstein downgraded Perrigo to Hold on the significant cut in guidance, the departure of CEO Papa, and the resulting uncertainty over the company's strategy. Kilstein adds pricing pressures in generics and competition in specialty medicines also present headwinds
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.